What if pain is more than just a mere alarm bell? New research in mice illuminates how pain neurons shield the gut from damage. Pain is one of evolution’s most effective mechanisms for detecting injury and letting us know that something is wrong. It acts as a warning system, telling us to stop and
News, analysis and comment from the Financial Times, the worldʼs leading global business publication
The awardees were presented with engraved clocks. NORTH ADAMS, Mass. — Massachusetts College of Liberal Arts on Saturday took time to recognize six of its alumni who...
The Cambridge, Massachusetts-based pharmaceutical company turned down China’s request to hand over the recipe for its mRNA vaccine because of commercial and safety concerns, the newspaper said, citing people involved in negotiations that took place between 2020 and 2021, adding that the vaccine make…
South Florida hospital leaders are concerned by the low numbers of people who are getting COVID boosters.
New Jersey, United States, Sept. 18, 2022 /DigitalJournal/ The mRNA Vaccines & Therapeutics Market research report provides all the information
Moderna, Inc. (NASDAQ:MRNA - Get Rating) Director Noubar Afeyan sold 10,000 shares of Moderna stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $134.00, for a total transaction of $1,340,000.00. Following the completion of the sale, the director now own…
RNA is a rather versatile technology and offers a number of advantages. RNA lacks genomic integration and its use results in transient expression of the
The week in pharma: action, reaction and insight – week to August 26
Brussels is warning of a vaccination “plateau” in the EU despite surging Covid-19 cases as it calls for member states to intensify campaigns ahead of the autumn and winter. EU health commissioner Stella Kyriakides said there was a risk that people were letting their guard down in the summer months a…
San Diego, California, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, reports that the shareholders of Emerald Health Therapeutics, Inc. (“Emerald”…
After netting its Series D round of funding in June, Resilience is not sitting around and resting on its laurels. The Bob Nelsen-backed contract manufacturer on Monday announced a new strategic collaboration with the Mayo Clinic. The relationship is centered around manufacturing biotherapeutics for…
The first Covid-19 vaccines that work on all variants might be available as early as 2024.
A little over two months after Trodelvy earned its first approval in China, Gilead is making moves to regain the drug’s rights in the country and the surrounding region. The big biopharma will pay Everest Medicines $280 million upfront for Trodelvy’s China rights and promise another $175 million in…
Today’s early morning highlights from the major news organizations.
A year and a half after rebranding, Viridian Therapeutics appears to have found a path forward. On Monday, the Waltham, MA-based biotech reported initial data from its Phase I/II trial of thyroid eye disease (TED) — and the results, while only in one of three treatment arms, look promising thus
Ventyx said it will begin testing its TYK2 inhibitor in multiple mid-stage clinical trials before the clock strikes 2023. The news comes just weeks before Bristol Myers Squibb is slated to find out whether it will be the first to secure a TYK2 drug approval, for its moderate to severe
In the lead-up to the FDA’s issuance of its first Covid-19 vaccine EUA to Pfizer in Dec. 2020, there was a lot of political grumbling and legitimate concern that the White House might try to speed up the authorization process to help former President Donald Trump’s reelection campaign. On the
While Roche has previously touted Polivy data for diffuse large B-cell lymphoma (DLBCL), the drug has faced some delays on the regulatory side. But the most recent news from the FDA looks encouraging for the Swiss pharma. Roche announced on Tuesday that the FDA accepted the company’s supplemental Bi…
Moderna, Inc. (NASDAQ:MRNA – Get Rating) Director Noubar Afeyan sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 10th. The shares were sold at an average price of $174.09, for a total transaction of $1,740,900.00. Following the sale, the director now owns…